Frans Herwig Jansen

Summary

Publications

  1. ncbi Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine
    Mathieu Verbeken
    Drug Quality and Registration group, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B 9000 Ghent, Belgium
    Malar J 10:51. 2011
  2. ncbi The pharmaceutical death-ride of dihydroartemisinin
    Frans Herwig Jansen
    Fondation ACT ion Afrique, Brussels, Belgium
    Malar J 9:212. 2010
  3. ncbi Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
    Frans Herwig Jansen
    ACT ion Afrique, Brussels, Belgium
    Malar J 10:70. 2011
  4. ncbi Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis
    Frans Herwig Jansen
    Fondation ACT ion Afrique, Bruxelles, Belgium
    Am J Trop Med Hyg 77:1005-9. 2007

Collaborators

  • Emmanuel Lesaffre
  • Mathieu Verbeken
  • Bram Baert
  • Sylvia Van Dorpe
  • Sultan Suleman
  • Christian Burvenich
  • Elien Vangheluwe
  • Luc Duchateau
  • Bart De Spiegeleer

Detail Information

Publications4

  1. ncbi Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine
    Mathieu Verbeken
    Drug Quality and Registration group, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B 9000 Ghent, Belgium
    Malar J 10:51. 2011
    ..However, until now, no exhaustive impurity profile of lumefantrine has been established, encompassing process-related and degradation impurities in active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs)...
  2. ncbi The pharmaceutical death-ride of dihydroartemisinin
    Frans Herwig Jansen
    Fondation ACT ion Afrique, Brussels, Belgium
    Malar J 9:212. 2010
    ..question rises how WHO and public-private partnerships, such as Medicine for Malaria venture (MMV), can support the production and marketing of anti-malarial drugs that do not even meet the International Pharmacopoeia requirements?..
  3. ncbi Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
    Frans Herwig Jansen
    ACT ion Afrique, Brussels, Belgium
    Malar J 10:70. 2011
    ..This combination permits a full therapy over 24 hours (dosing interval being 12 hours). It is recommended that this combination should be tested in future field studies of IPTi...
  4. ncbi Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis
    Frans Herwig Jansen
    Fondation ACT ion Afrique, Bruxelles, Belgium
    Am J Trop Med Hyg 77:1005-9. 2007
    ..Annual follow-up on the data published is intended to reveal the changes in the relative drug efficacy values of ACTs...